Dr. William Williams reports

BRIACELL PRESENTS ROBUST ANTI-CANCER ACTIVITY OF BRIA-OTS+ IN PRECLINICAL CANCER MODELS

Briacell Therapeutics Corp. is presenting positive data from its preclinical Bria-OTS+ platform at the 2026 American Association for Cancer Research annual meeting taking place April 17 to April 22 at the San Diego Convention Center in San Diego, Calif.

Title:  Re-Engineering Cancer Vaccines: Bria-OTS+ Integrates Innate and Adaptive Immunity for Broad and Persistent Anti-Tumor Responses

Session category:  clinical research

Session title:  Vaccines and Other Immunomodulatory Agents

Session:  April 21, 2026, at 2 to 5 p.m.

Location:  poster section 49

Poster board No.:  12

Poster No.:  6701

Summary: Bria-OTS+ is a personalized, off-the-shelf, next-generation genetically engineered whole-cell cancer immunotherapy platform designed to enhance efficacy and safety. Its results demonstrate that Bria-OTS+ activates key components of both the innate and adaptive immune systems to broadly target and destroy cancer cells across solid tumours. These effects include co-ordinated activation of CD4+ and CD8+ T-cells, NK-cells, NKT-cells, dendritic cells, and B-cells, together with increased cytokine release and sustained immune competence without exhaustion -- helping address an important mechanism of cancer progression.

Data presented include the following:

• Rapid activation of innate and adaptive immune responses: Bria-BRES+ (breast cancer) and Bria-PROS+ (prostate cancer) drove early activation and proliferation of key immune cells including CD4+ and CD8+ T-cells, NK-cells, and NKT cells, enhanced cytotoxic activity against parental tumour targets, and increased CD80/CD86 expression on dendritic and B-cells, consistent with improved antige npresentation.
• Sustained, long-lasting and targeted anti-tumour activity: Bria-BRES+ and Bria-PROS+ generated durable cytokine responses and maintained cytotoxic, serial killing activity through repeated cancer cell challenges without evidence of functional exhaustion. Bria-OTS+ also showed limited induction of immunosuppressive cell populations including regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs).
• Broad tumour recognition may reduce escape risk: Bria-BRES+ and Bria-PROS+ cells demonstrated anti-tumour activity against multiple tumour targets, supporting the potential of Bria-OTS+ to drive broad, cross-tumour immune responses, reduce immune escape and limit cancer progression.
• Bria-OTS+ proposed mechanism of action: Following intradermal administration, Bria-OTS+ is designed to activate T-cells and NK-cells directly, while professional antigen-presenting cells (APCs) take up tumour-specific antigens, migrate to regional lymph nodes and prime tumour-specific T-cells to drive a systemic anti-tumour immune response.

Miguel A. Lopez-Lago, PhD, Briacell's chief scientific officer, commented: "We are thrilled with our data showing early, strong and long-lasting anti-cancer activity of Bria-OTS+ in multiple cancer models, boosting the immune system response and potentially overcoming common cancer cell resistance mechanisms. Our findings strongly support targeted anti-cancer effects of Bria-OTS+ and warrant additional testing of the Bria-OTS+ platform in clinical settings."

"Based on these promising preclinical findings, we are advancing Bria-OTS+ with the goal of entering the clinic for our first indications of metastatic breast cancer and prostate cancer later this year, with additional indications (lung cancer and melanoma) planned for 2027," added Dr. William V. Williams, Briacell's president and chief executive officer.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.